RNU6-922P

Across TCGA pan-cancer cohorts, RNU6-922P RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated RNU6-922P data layer.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher RNU6-922P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-922P expression acts as an unfavorable survival marker.

DLBC, ESCA, and STAD are the cancer types where RNU6-922P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Tertile	III,IV	0.118	0.774	<.001	81	view →
ESCA	OS	Tertile	III,IV	0.238	0.605	<.001	42	view →
STAD	DFS	Tertile	II,III,IV	0.494	0.648	.013	39	view →
KIRC	DFS	Tertile	IV	0.126	0.658	<.001	36	view →
MESO	OS	Tertile	III,IV	0.069	0.580	<.001	36	view →
SKCM	DFS	Tertile	All	0.058	0.762	<.001	27	view →
PAAD	DFS	Tertile	III,IV	0.118	0.734	.014	18	view →
GBM	OS	Tertile	All	0.079	0.422	<.001	18	view →
LIHC	DFS	Tertile	All	0.204	0.557	.035	18	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

RNU6-922P–DLBC (DFS)

Open the DLBC breakdown →